ABSTRACT
Successful cancer therapy has long been among the greatest challenges in medicine. In order to be effective, a targeted therapy must first localize to cancer cells and subsequently cause cell death. The osseous structures are a very common site of bone metastases in many cancers, most notably breast and prostate cancers. Somatostatin is a hormone whose receptors are overexpressed on the majority of neuroendocrine cancers such as pancreatic neuroendocrine cancers and carcinoid tumors. Targeted systemic cancer radiotherapies have been successful, notably in thyroid cancer, but the potential in largely unrealized. The small size of the molecule and its lack of nonspecific binding will potentially allow for very rapid targeting of the bispecific construct with minimal normal tissue exposure, greatly improving the therapeutic ratio. The most important barriers to wider acceptance of targeted systemic radiotherapies are not necessarily scientific.
